Poser, Wolfgang

[["dc.bibliographiccitation.firstpage","469"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Drug and Alcohol Review"],["dc.bibliographiccitation.lastpage","470"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Vormfelde, Stefan Viktor"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T10:31:00Z"],["dc.date.available","2018-11-07T10:31:00Z"],["dc.date.issued","2000"],["dc.identifier.isi","000165996100014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43993"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Carfax Publishing"],["dc.relation.issn","0959-5236"],["dc.title","How to count methadone-related deaths"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","86"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","95"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: (1) To perform a 9-year study of abstinence, lapse, and relapse in 180 chronic alcoholic patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence. Method: This prospective open treatment study evaluates the long-term course of drinking outcomes and AD use of 180 chronic alcoholics consecutively admitted from 1993 to 2002. Subsamples are compared for (1) sham-AD versus verum-AD (disulfiram/calcium carbimide), (2) coped lapses versus finally detrimental lapses versus malignant relapses, and (3) AD use for 13 to 20 versus {.extbackslash}textgreater 20 months. Results: In this 9-year study, the cumulative probability of not having relapsed was 0.52, and that of not having consumed any alcohol was 0.26. Despite long-term use, disulfiram/calcium carbimide was well tolerated. Patients on sham-AD (due to contraindications to verum-AD) showed higher cumulative abstinence probability than patients on verum (S {.extbackslash}textequals 0.86 vs. S {.extbackslash}textequals 0.49, p {.extbackslash}textequals 0.03). Detrimental lapses and malignant relapses occurred earlier than successfully coped lapses (p {.extbackslash}textless 0.001); patients with detrimental lapse and with malignant relapse had rewer days of AD intake and less subsequent days without AD than patients with coped lapse (p {.extbackslash}textless 0.001). The cumulative abstinence probability was S {.extbackslash}textequals 0.75 for patients with long-term intake compared with S {.extbackslash}textequals 0.50 for patients who stopped AD between months 13 and 20 (p {.extbackslash}textless 0.001). Conclusions: An abstinence rate of {.extbackslash}textgreater 50{.extbackslash}textpercent in this 9-year study strongly supports the concept of comprehensive, long-term outpatient treatment of alcoholics. Supervised, guided intake of AD, also over extended periods, can be used as a predominantly psychologically acting ingredient of successful alcoholism therapy."],["dc.identifier.doi","10.1111/j.1530-0277.2006.00013.x"],["dc.identifier.gro","3150523"],["dc.identifier.pmid","16433735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7295"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0145-6008"],["dc.title","Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Clinical Pharmacology"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T09:58:38Z"],["dc.date.available","2018-11-07T09:58:38Z"],["dc.date.issued","2002"],["dc.format.extent","S90"],["dc.identifier.isi","000179032800080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37404"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","4th Annual Congress on Clinical Pharmacology"],["dc.relation.eventlocation","WIESBADEN, GERMANY"],["dc.relation.issn","0031-6970"],["dc.title","Predicting the potential for abuse and dependence of new drugs"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","273"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","85"],["dc.contributor.author","Sachse-Seeboth, C."],["dc.contributor.author","Pfeil, J."],["dc.contributor.author","Sehrt, D."],["dc.contributor.author","Meineke, I."],["dc.contributor.author","Tzvetkov, M."],["dc.contributor.author","Bruns, E."],["dc.contributor.author","Poser, W."],["dc.contributor.author","Vormfelde, S. V."],["dc.contributor.author","Brockmöller, J."],["dc.date.accessioned","2019-07-09T11:52:51Z"],["dc.date.available","2019-07-09T11:52:51Z"],["dc.date.issued","2008"],["dc.description.abstract","The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Δ9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9 2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9 3/ 3 homozygotes than in CYP2C9 1/ 1 homozygotes. CYP2C9 3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9 3 variant may influence both the therapeutic and adverse effects of THC."],["dc.identifier.doi","10.1038/clpt.2008.213"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60294"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","271"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Siren, A. L."],["dc.contributor.author","Knerlich, F."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Bruck, Wolfgang W."],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T09:17:30Z"],["dc.date.available","2018-11-07T09:17:30Z"],["dc.date.issued","2001"],["dc.description.abstract","Using immunohistochemistry, expression of erythropoietin (EPO), a hypoxia-inducible neuroprotective factor, and its receptor (EPOR) were investigated in human brain tissue after ischemia/hypoxia. Autopsy brains of neuropathologically normal subjects were compared to those with ischemic infarcts or hypoxic damage. In normal brain, weak EPO/EPOR immunoreactivity was mainly neuronal. In fresh infarcts, EPO immunoreactivity appeared in vascular endothelium, EPOR in microvessels and neuronal fibers. In older infarcts reactive astrocytes exhibited EPO/EPOR immunoreactivity. Acute hypoxic brain damage was associated with vascular EPO expression, older hypoxic damage with EPO/EPOR immunoreactivity in reactive astrocytes. The pronounced up-regulation of EPO/EPOR in human ischemic/hypoxic brains underlines their role as an endogenous neuroprotective system and suggests a novel therapeutic potential in cerebrovascular disease for EPO, a clinically well-characterized and safe compound."],["dc.identifier.isi","000167526200013"],["dc.identifier.pmid","11307627"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28185"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0001-6322"],["dc.title","Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruether, Eckhart"],["dc.date.accessioned","2018-11-07T08:47:50Z"],["dc.date.available","2018-11-07T08:47:50Z"],["dc.date.issued","2010"],["dc.format.extent","49"],["dc.identifier.isi","000281281100169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21059"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cambridge Univ Press"],["dc.publisher.place","New york"],["dc.relation.conference","27th CINP Congress Meeting 2010"],["dc.relation.eventlocation","Hong Kong, PEOPLES R CHINA"],["dc.relation.issn","1461-1457"],["dc.title","Pontine myelinolysis and hyponatremia associated with carbamazepine treatment in patients with alcohol dependence"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Wacker, S."],["dc.contributor.author","Weissbeck-Schauenburg, R."],["dc.contributor.author","Schauenburg, Henning"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T10:57:21Z"],["dc.date.available","2018-11-07T10:57:21Z"],["dc.date.issued","2007"],["dc.format.extent","162"],["dc.identifier.isi","000253318800331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50222"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0028-2804"],["dc.title","Short term combined outpatient-inpatient group psychotherapy for alcohol and benzodiazepine dependence - concept and results"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","German Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","7"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Jacobs, Stefan"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Schneider, Udo"],["dc.contributor.author","Cimander, Konrad"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2019-07-10T08:13:27Z"],["dc.date.available","2019-07-10T08:13:27Z"],["dc.date.issued","2009"],["dc.description.abstract","Objective: Previous reports on heroin and cocaine addicts showed drug-related and gender differences in psychiatric comorbidity, which has relevant consequences for treatment. However, studies vary substantially with respect to methods and timeframes. Studies on German patient groups are scarce. Methods: Data on psychiatric and somatic comorbidity, substance addiction history, present intake patterns and sociodemography were obtained from 43 female (n=11) and male (n=32) heroin and cocaine addicts in acute inpatient detoxification treatment or specified long-term treatment. A European Addiction-Severity-Index (EuropASI) based centre questionnaire and the Mini-DIPS were applied. Results: Treatment groups did not differ in psychiatric comorbidity. Female subjects, however, had a significantly higher prevalence of psychiatric comorbid diagnoses (p<.05), mostly anxiety and affective disorders which significantly correlated with low occupational status (p<.05).Patients in long-term treatment abused more other substances and had an earlier onset of regular substance abuse (in particular alcohol and cannabis) (p<.05). Conclusion: Heroin and cocaine addicted females are more likely than males to have affective and anxiety disorders. Long-term treatment attenders appear to be more severely addicted (earlier onset and additional abuse) than acute treatment patients but do not differ in comorbidity. However, no axis-II diagnoses were recorded and the sample-size was small. Results should be regarded as preliminary (German J Psychiatry 2009; 12: 1-7)."],["dc.identifier.fs","541930"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5950"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61249"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1455-1033"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Psychiatric Comorbidity and Gender Effects in Heroin and Cocaine-Addicted Patients in Specified Long-Term Treatment and Acute Inpatient Detoxification Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Bartels, C."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:56:35Z"],["dc.date.available","2018-11-07T10:56:35Z"],["dc.date.issued","2005"],["dc.format.extent","257"],["dc.identifier.isi","000232591900140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50048"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Longterm follow-up of 180 chronic alcoholics during and after comprehensive integrated outpatient treatment: Relation of deterrent medication (DM) and outcome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","283"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Kress, I."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T10:48:48Z"],["dc.date.available","2018-11-07T10:48:48Z"],["dc.date.issued","2004"],["dc.description.abstract","A selective and sensitive HPLC method is described for therapeutic drug monitoring of the antidepressant drug mirtazapine and its active metabolite desmethylmirtazapine. Liquid/solid extraction with C, cartridges was used for cleanup of plasma samples. The chromatographic separation was carried out on a phenylhexyl column. No interference from other coadministered antidepressants has been observed in 234 samples from 184 patients. The calibration range used was from 1 ng/mL to 100 ng/mL. The analytic method has proven robust and well suited for therapeutic drug monitoring. In addition to qualitative and quantitative validation data for the assay method, concentration measurements in samples from patients on mirtazapine therapy and the relevant dosing information are presented. Median drug levels after a 15-mg dose were 37 ng/mL mirtazapine and 20 ng/mL desmethylmirtazapine. When a 60-mg dose was administered, median concentrations of 83 ng/mL mirtazapine and 65 ng/mL desmethylmirtazapine were found."],["dc.identifier.doi","10.1097/00007691-200406000-00010"],["dc.identifier.isi","000222196600009"],["dc.identifier.pmid","15167628"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48284"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0163-4356"],["dc.title","Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]